• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Thromb J . Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study

tetano

Editor, Senior Moderator
Thromb J


. 2023 Jul 28;21(1):80.
doi: 10.1186/s12959-023-00524-0. Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study

Emily Corneo[SUP] 1 [/SUP], Rafael Garbelotto[SUP] 1 2 [/SUP], Gabriele Prestes[SUP] 1 [/SUP], Carolina Saibro Girardi[SUP] 3 [/SUP], Lucas Santos[SUP] 3 [/SUP], Jose Claudio Fonseca Moreira[SUP] 3 [/SUP], Daniel Pens Gelain[SUP] 3 [/SUP], Glauco A Westphal[SUP] 4 [/SUP], Emil Kupek[SUP] 5 [/SUP], Roger Walz[SUP] 6 [/SUP], Cristiane Ritter[SUP] 1 2 [/SUP], Felipe Dal-Pizzol[SUP] 7 8 9 [/SUP]



Affiliations
Abstract

Background: Because severe acute respiratory syndrome coronarivus 2 (SARS-CoV-2) leads to severe conditions and thrombus formation, evaluation of the coagulation markers is important in determining the prognosis and phenotyping of patients with COVID-19.
Methods: In a prospective study that included 213 COVID-19 patients admitted to the intensive care unit (ICU) the levels of antithrombin, C-reactive protein (CRP); factors XI, XII, XIII; prothrombin and D-dimer were measured. Spearman's correlation coefficient was used to assess the pairwise correlations between the biomarkers. Hierarchical and non-hierarchical cluster analysis was performed using the levels of biomarkers to identify patients´ phenotypes. Multivariate binary regression was used to determine the association of the patient´s outcome with clinical variables and biomarker levels.
Results: The levels of factors XI and XIII were significantly higher in patients with less severe COVID-19, while factor XIII and antithrombin levels were significantly associated with mortality. These coagulation biomarkers were associated with the in-hospital survival of COVID-19 patients over and above the core clinical factors on admission. Hierarchical cluster analysis showed a cluster between factor XIII and antithrombin, and this hierarchical cluster was extended to CRP in the next step. Furthermore, a non-hierarchical K-means cluster analysis was performed, and two phenotypes were identified based on the CRP and antithrombin levels independently of clinical variables and were associated with mortality.
Conclusion: Coagulation biomarkers were associated with in-hospital survival of COVID-19 patients. Lower levels of factors XI, XII and XIII and prothrombin were associated with disease severity, while higher levels of both CRP and antithrombin clustered with worse prognosis. These results suggest the role of coagulation abnormalities in the development of COVID-19 and open the perspective of identifying subgroups of patients who would benefit more from interventions focused on regulating coagulation.

Keywords: COVID-19; Cluster phenotyping; Coagulation; Coagulation factors; Prognostication.

 
Back
Top Bottom